Avidity Biosciences Inc. (RNA) stock expected to rise by 443.53%: What’s driving the optimism?

Avidity Biosciences Inc. [RNA] stock prices are down -0.71% to $6.96 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RNA shares have gain 5.94% over the last week, with a monthly amount drifted -15.64%, and not seem to be holding up well over a long-time horizon.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


On 7, September 2023, Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs. In a post published today on Yahoo Finance, Avidity supports World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, FSHD Society Walk & Roll to Cure FSHD and Global Genes Week in RARE.

From an analyst’s perspective:

Avidity Biosciences Inc. [NASDAQ: RNA] stock has seen the most recent analyst activity on May 22, 2023, when Evercore ISI upgraded its rating to a Outperform but kept the price target unchanged to $20 for it.

The stock price of Avidity Biosciences Inc. [RNA] has been fluctuating between $6.40 and $25.74 over the past year. Currently, Wall Street analysts expect the stock to reach $37.83 within the next 12 months. Avidity Biosciences Inc. [NASDAQ: RNA] shares were valued at $6.96 at the most recent close of the market. An investor can expect a potential return of 443.53% based on the average RNA price forecast.

Analyzing the RNA fundamentals

The most recent quarter, Avidity Biosciences Inc. [NASDAQ:RNA] reported sales of 2.32 billion, representing a surge of 4.50%. During this period, the public company’s revenue per employee was $49,591, while its income per employee was -$935,457. Gross Margin for this corporation currently stands at +84.96% with Operating Margin at -1939.65%, Pretax Margin comes in at -1886.33%, and Net Margin reading is -1886.33%. To continue investigating profitability, this company’s Return on Assets is posted at -32.63, Equity is -36.27, Total Capital is -36.44, and Invested Capital is -35.62. Taking a look at the Principal structure of this organization reveals enduring liabilities to the total capital at 1.82 and enduring liabilities to the whole assets at 1.67.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.72 points at the first support level, and at 6.48 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.29, and for the 2nd resistance point, it is at 7.62.

Avidity Biosciences Inc. [RNA] reported earnings per share of -$0.66 for its fiscal quarter that ended on 6/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.8/share, meaning a difference of $0.14 and a surprise factor of 17.50%. By comparison, the stated earnings for the previous quarter ended on 3/30/2023 were -$0.74 per share as compared to estimates of -$0.85 per share, a difference of $0.11 representing a surprise of 12.90%.

Ratios To Look Out For

It’s worth pointing out that Avidity Biosciences Inc. [NASDAQ:RNA]’s Current Ratio is 13.10. In addition, the Quick Ratio stands at 12.00 and the Cash Ratio stands at 11.77. Considering the valuation of this stock, the price to sales ratio is 125.49, the price to book ratio is 2.68.

Transactions by insiders

Recent insider trading involved LEVIN ARTHUR A, Director, that happened on Mar 15 when 100.0 shares were sold. Chief Scientific Officer, LEVIN ARTHUR A completed a deal on Feb 14 to sell 10000.0 shares. Meanwhile, President and CEO Boyce Sarah sold 3221.0 shares on Feb 03.